- Home
- QNRX vs XBIO Comparison
QNRX vs XBIO Comparison
Compare QNRX & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNRX
- XBIO
- Stock Information
- Founded
- QNRX 2018
- XBIO N/A
- Country
- QNRX United States
- XBIO United States
- Employees
- QNRX N/A
- XBIO N/A
- Industry
- QNRX Medical/Dental Instruments
- XBIO Biotechnology: Pharmaceutical Preparations
- Sector
- QNRX Health Care
- XBIO Health Care
- Exchange
- QNRX Nasdaq
- XBIO Nasdaq
- Market Cap
- QNRX 4.8M
- XBIO 4.4M
- IPO Year
- QNRX N/A
- XBIO N/A
- Fundamental
- Price
- QNRX $7.90
- XBIO $11.96
- Analyst Decision
- QNRX
- XBIO Hold
- Analyst Count
- QNRX 0
- XBIO 1
- Target Price
- QNRX N/A
- XBIO N/A
- AVG Volume (30 Days)
- QNRX 130.9K
- XBIO 28.4K
- Earning Date
- QNRX 11-06-2025
- XBIO 11-11-2025
- Dividend Yield
- QNRX N/A
- XBIO N/A
- EPS Growth
- QNRX N/A
- XBIO N/A
- EPS
- QNRX N/A
- XBIO N/A
- Revenue
- QNRX N/A
- XBIO $2,446,221.00
- Revenue This Year
- QNRX N/A
- XBIO $1.99
- Revenue Next Year
- QNRX N/A
- XBIO $20.00
- P/E Ratio
- QNRX N/A
- XBIO N/A
- Revenue Growth
- QNRX N/A
- XBIO N/A
- 52 Week Low
- QNRX $5.01
- XBIO $2.20
- 52 Week High
- QNRX $54.95
- XBIO $5.27
- Technical
- Relative Strength Index (RSI)
- QNRX 57.03
- XBIO 95.26
- Support Level
- QNRX $7.19
- XBIO $2.81
- Resistance Level
- QNRX $7.92
- XBIO $3.29
- Average True Range (ATR)
- QNRX 0.44
- XBIO 0.40
- MACD
- QNRX 0.04
- XBIO 0.63
- Stochastic Oscillator
- QNRX 82.59
- XBIO 100.00
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.